Biotest AG
44Patents
33Active
44Granted
49Portfolio score
Filing activity: Jan 4, 1989 → Dec 2, 2022 · 17 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7452981B2 | Humanized anti-CD4 antibody with immunosuppressive properties | Chemistry; Metallurgy | 75 | Expired |
| US6120989A | Isolated human cytomegalovirus polypeptides and uses thereof | Emerging Cross-Sectional Technologies | 30 | Expired |
| US7659247B2 | Production of a von Willebrand factor preparation having a high specific activity | Chemistry; Metallurgy | 24 | Active |
| US8673304B2 | Humanized anti-CD4 antibody with immunosuppressive properties | Chemistry; Metallurgy | 19 | Active |
| US8440806B2 | Humanized anti-CD4 antibody with immunosuppressive properties | Chemistry; Metallurgy | 19 | Active |
| US9758581B2 | Humanized anti-CD4 antibody with immunosuppressive properties | Chemistry; Metallurgy | 18 | Active |
| US9011864B2 | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates | Chemistry; Metallurgy | 16 | Active |
| US5523214A | Method of visually demonstrating the presence of microorganisms, identifying them, and testing them for sensitivity to antibiotics with redox indicators | Emerging Cross-Sectional Technologies | 11 | Expired |
| US10117932B2 | Uses of immunoconjugates targeting CD138 | Human Necessities | 7 | Active |
| US6168930A | Change in system | Chemistry; Metallurgy | 7 | Expired |
| US9289509B2 | Uses of immunoconjugates targeting CD138 | Performing Operations; Transporting | 6 | Active |
| US5213963A | Procedure for finding and identifying red cell antibodies by means of the solid phase method | Emerging Cross-Sectional Technologies | 6 | Expired |
| US6617126B1 | Method for improving the growth and colorimetric detection of bacteria, yeasts, fungi or cocci | Chemistry; Metallurgy | 5 | Expired |
| US9221914B2 | Agents targeting CD138 and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US8956607B2 | Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE) | Chemistry; Metallurgy | 4 | Active |
| US9387261B2 | Immunoconjugates targeting CD138 and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US4925786A | Method of determining blood groups by the solid-phase procedure with blood-group specific antibodies of the immunoglobulin M. type and support and kit for carrying out the method | Physics | 3 | Expired |
| US8840898B2 | Immunoconjugates targeting syndecan-1 expressing cells and use thereof | Human Necessities | 3 | Active |
| US6177080A | Polypeptides encoded by Kaposi sarcoma-associated herpes virus the use thereof in diagnosis and therapy | Chemistry; Metallurgy | 2 | Expired |
| US8852871B2 | Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) | Chemistry; Metallurgy | 2 | Active |
| US7939643B2 | Production of a von Willebrand factor preparation using hydroxylapatite | Chemistry; Metallurgy | 2 | Active |
| US8586715B2 | Humanized anti-CD4 antibody with immunosuppressive properties | Chemistry; Metallurgy | 1 | Active |
| US6908745B2 | Gamma sterilizable culture medium for the identification of yeasts and fungi | Chemistry; Metallurgy | 1 | Expired |
| US9243056B2 | Process for preparing an immunoglobulin composition | Chemistry; Metallurgy | 1 | Active |
| US9334325B2 | Method for treating psoriasis | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.